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Abstract
Aims/hypothesis The aim of this work was to examine whether glycaemic control has improved in those with type 1 diabetes in
Scotland between 2004 and 2016, and whether any trends differed by sociodemographic factors.
Methods We analysed records from 30,717 people with type 1 diabetes, registered anytime between 2004 and 2016 in the
national diabetes database, which contained repeated measures of HbA1c. An additive mixed regression model was used to
estimate calendar time and other effects on HbA1c.
Results Overall, median (IQR) HbA1c decreased from 72 (21) mmol/mol [8.7 (4.1)%] in 2004 to 68 (21)mmol/mol (8.4 [4.1]%) in
2016. However, all of the improvement across the period occurred in the latter 4 years: the regression model showed that the only
period of significant change in HbA1c was 2012–2016 where there was a fall of 3 (95% CI 1.82, 3.43) mmol/mol. The largest
reductions in HbA1c in this period were seen in children, from 69 (16) mmol/mol (8.5 [3.6]%) to 63 (14) mmol/mol (7.9 [3.4]%),
and adolescents, from 75 (25) mmol/mol (9.0 [4.4]%) to 70 (23) mmol/mol (8.6 [4.3]%). Socioeconomic status (according to
Scottish Index of Multiple Deprivation) affected the HbA1c values: from the regression model, the 20% of people living in the
most-deprived areas had HbA1c levels on average 8.0 (95%CI 7.4, 8.9) mmol/mol higher than those of the 20% of people living in
the least-deprived areas. However this difference did not change significantly over time. From the regression model HbA1c was on
average 1.7 (95% CI 1.6, 1.8) mmol/mol higher in women than in men. This sex difference did not narrow over time.
Conclusions/interpretation In this high-income country, we identified a modest but important improvement in HbA1c since 2012
that was most marked in children and adolescents. These changes coincided with national initiatives to reduce HbA1c including
an expansion of pump therapy. However, in most people, overall glycaemic control remains far from target levels and further
improvement is badly needed, particularly in those from more-deprived areas.
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Introduction
Type 1 diabetes is associated with a substantial reduction in
life span [1] and a threefold increase in the rate of cardiovas-
cular disease compared with individuals without diabetes and
remains a common cause of end-stage renal disease and loss
of vision [2]. Poor glycaemic control as indicated by HbA1c is
a key determinant of such complications and lowering HbA1c
reduces complications and prolongs survival rate [3].
However, achieving good levels of control remains a chal-
lenge in all countries. In an international study of type 1 dia-
betes in 19 countries in 2014, most people with type 1 diabetes
had higher than recommended levels of HbA1c [4]. Of those
aged 15 years and more, median levels of HbA1c were highest
in Scotland.
As has happened to varying extents in other high-income
countries, the publicly funded National Health Service (NHS)
Scotland has employed several important changes to improve
glycaemic control in type 1 diabetes in recent years [5].
Provision of insulin pumps has increased from 8.4% to
34.4% in those under 18 years and from 2.5% to 8.3% in
adults between 2011 and 2016. In addition, during this period,
policies were instituted to enhance access to early structured
education and provision of psychological interventions and
there was a slight expansion of continuous glucose monitoring
(CGM). A national survey showed that the proportion of
individuals with type 1 diabetes who achieved HbA1c
≤58 mmol/mol (7.5%) in Scotland slightly improved from
21.5% in 2013 to 24.5% in 2016 [6]. This survey reports the
overall population HbA1c annually but does not test whether
year-on-year changes represent significant trends or random
fluctuations and does not explore detailed trends by age, sex or
socioeconomic strata. Therefore, we analysed a nationwide
diabetes register in Scotland enriched for patient characteris-
tics and repeated measurements of HbA1c to assess whether
the significance of trends was beyond random fluctuations and
to measure their consistency across age group, sex and socio-
economic strata. We sought evidence of whether healthcare
innovations have had any impact on HbA1c in this high-
income country.
1376 Diabetologia (2019) 62:1375–1384
Methods
Study population The Scottish Care Information-Diabetes
Collaboration (SCI-Diabetes) database has been described
[2]. This nationwide electronic healthcare record database
captures registration of all patients assigned a diagnosis of
diabetes in primary or secondary care healthcare information
systems. Since 2004, the database has almost complete nation-
al coverage of all prevalent and incident cases of diabetes. All
but five of 1076 general practices nationwide contributed data
continuously over this period, yielding over 99.5% coverage
of all diagnosed cases of diabetes. Type 1 diabetes was iden-
tified using information on age, drug prescription and clinical
description of the type of diabetes. This approach has previ-
ously been validated in SCI-Diabetes against inpatient re-
cords, with greater than 99% accuracy. Those whose type of
diabetes was not known were excluded. The study was ap-
proved by the Scotland A Research Ethics Committee,
Privacy (Caldicott) Guardians for the 14 Scottish Health
Boards and the Information Services Division (ISD) of NHS
National Services Scotland Privacy Advisory Committee.
From SCI-Diabetes, we selected all patients alive with
type 1 diabetes at any time from 2004 to 2016 with re-
corded age at diabetes diagnosis, sex, ethnic group, health
board, the Scottish Index of Multiple Deprivation (SIMD)
and date of birth and who had more than one measure-
ment of HbA1c (N = 30,717). Thus, in any 1 year the data
comprise that from prevalent cases of type 1 diabetes
alive and any newly incident cases arising in that year.
The SIMD is a residential area-based proxy measure of
individual socioeconomic status [7].
Measurements of HbA1c and other variables HbA1c was mea-
sured using a variety of clinical methods, all of which were
aligned to the assay used in the DCCT. In Scotland, HbA1c
was recorded in % in earlier years then converted into the
International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC) units (mmol/mol) in 2010–
2011. We used all available data in the clinical record on
HbA1c measures throughout the study as the outcome of
interest.
Data were categorised into six age groups at baseline (in
years): <13, 13–18, 19–24, 25–44, 45–64 and >64. For each
subsequent year they contributed data to the analysis, an indi-
vidual may have been categorised into different age groups in
the regression analysis as they aged.
‘Poor’ glycaemic control was defined as HbA1c >75 mmol/
mol (9%) and ‘good’ glycaemic control was defined as HbA1c
≤58 mmol/mol (7.5%) in individuals aged ≤18 years and
≤53 mmol/mol (7%) in individuals aged >18 years as defined
by the ADA [8]. We also considered the National Institute for
Health and Care Excellence (NICE) guidelines for good
glycaemic control of ≤48 mmol/mol (6.5%) [9].
Statistical analysisMedians and interquartile ranges were pre-
sented across years and separated by sex, SIMD category and
age group. We used a fully flexible modelling approach with
unrestrictive assumptions to capture non-linear trends in
HbA1c over time. This offered the potential to uncover hidden
significant trends in HbA1c rather than taking a group-based
trajectory approach [10]. For this reason, changes in log trans-
formed HbA1c between 2004 and 2016 were assessed by
fitting an additive mixed regression model with patient iden-
tifier as a random effect and a first-order autoregressive cor-
relation structure to account for temporal dependencies in
these data. This approach allowed us to capture non-linear
trends in HbA1c over time through regularised, non-
parametric smooth functions, therefore relaxing any assump-
tions surrounding the nature of all relationships. We used the
mgcv package version 1.8-28 in R [11] (downloaded from
https://www.stats.bris.ac.uk/R/).
The model included age at diagnosis of diabetes, current
age group, sex, ethnic group and SIMD band. We included
interaction terms, or smooth functions, for current age group,
sex and SIMD band over time in order to identify trends in
HbA1c in each category of these factors. Smooth functions
were estimated by cubic regression splines. To account for
seasonality [12], a smooth function for month was estimated
by a cyclic penalised cubic regression spline to allow continu-
ity between December and January in the following year.
Significant periods of change were identified in each time
series by estimating the rate of change along a grid of time
points between 2004 and 2016. Bonferroni correction was
used to maintain an overall significance level of 0.05.
We selected a grid of points and estimated the derivative
(i.e. the gradient) of each smooth function at these points. This
was repeated, increasing the chosen grid of time points by a
small amount ϵ = 1e−6. We then compared the change in de-
rivative (equivalent to comparing the second derivative) be-
tween the closely selected points. A positive change indicates
the function is increasing, thereby identifying periods of sig-
nificant increase, whereas a negative change indicates the
function is decreasing and no change indicated the function
is stationary [13].
In the multivariate regression model to test significance of
calendar time trends, we adjusted for age, sex, SIMD band,
age at onset of diabetes, health board and season. We used
non-parametric bootstraps with replacement of fitted values
in order to infer significant differences in change between
age groups, sexes and SIMD bands.
Results
Between 2004 and 2016we had amedian of 21measurements
per individual (interquartile range 15) across the 13 year peri-
od. In any given year the median number of HbA1c
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measurements per individual varied from 1 to 2 (Table 1). The
median duration of diabetes was 14 years in 2004 and 19 years
in 2016. Within each year, between 0.048% and 0.01% of
people were in the first year of diagnosis (Table 1).
The distribution of the characteristics of the population at
the midpoint of each year studied were very stable across the
time period studied, with the male sex making up 55% of the
population in 2004 and 54% in 2016 and the median age of
diabetes onset being 20 years in men/boys and 18 years in
women/girls consistently across the period.
The study was carried out in accordance with the ethical
principles in the Declaration of Helsinki as revised in 2008.
Calendar time trends in HbA1c across the population of
Scotland with type 1 diabetes from 2004 to 2016 In the over-
all population, the median (IQR) HbA1c fell from 72 (21)
mmol/mol (8.7 [4.1]%) in 2004 to 68 (21) mmol/mol (8.4
[4.1]%) in 2016, a fall of six percentage points (Table 1, Fig.
1a). There was a substantial fall in the proportion of people
with poor glycaemic control, defined as HbA1c >75mmol/mol
(9%), from 42% in 2004 to 36% 2016 (Table 1, Fig. 2a). The
proportion of people at target HbA1c (≤53 mmol/mol [7%] in
adults and ≤58 mmol/mol [7.5%] in children and adolescents)
improved from 11% to 15% but only small proportions of
people attained the NICE target of 48 mmol/mol (6.5%) at
any time (4% in 2004 and 5% in 2016). There was a transient
rise in HbA1c during the period 2010–2012 (Fig. 1a). Note all
figures use the modelled estimates and the confidence limits
for the time trend from the models.
In a regression model combining data across the study pe-
riod, variables associated with significant variation in HbA1c
included age, sex, age at diagnosis of type 1 diabetes, health
board of treatment, SIMD band and season (electronic supple-
mentary material [ESM] Table 1); HbA1c was significantly
lower in summer and higher in winter. Therefore, in the mul-
tivariate regression model, we adjusted for these variables.
The calendar periods of significant change in HbA1c at popu-
lation level were 2010–2012 (Fig. 1a) where there was a rise
of 1 (95%CI 0.8, 1.45) mmol/mol and then 2012–2016 where
there was a fall of 3 (95% CI 1.82, 3.43) mmol/mol (Fig. 1a).
Thus, all of the improvement across the period 2004–2016
occurred in the latter 4 years of the period.
HbA1c trends by age From 2012, a significant decline in
HbA1c was seen in all age groups, with the most marked
decline in the two younger age groups <13 years and 13–
18 years (Fig. 1b and ESM Table 2). Median HbA1c between
2012 and 2016 fell significantly from 69 (16) to 63 (14)
mmol/mol (8.5 [3.6]% to 7.9 [3.4]%) and from 75 (25) to 70
(23) mmol/mol (9.0 [4.4]% to 8.6 [4.3]%) in these groups,
respectively. Consistently, the proportion with poor glycaemic
control (>75 mmol/mol [9%]) fell most in this time period in
these two age groups, from 32% to 16% and from 51% to 42%
respectively (ESM Table 2, Fig. 2b). However, across all age
groups, the proportions with poor control remained high in
2016, being highest (48%) in those aged 19–24 years (Fig.
2b and ESM Table 2). The proportion of those aged <13 years
and 13–18 years with good glycaemic control increased be-
tween 2012 and 2016 but in these, as with other age groups,
still only a minority of people achieved target HbA1c values,
whether considering the NICE targets of 48 mmol/mol (6.5%)
or age-specific targets of 53 and 58 mmol/mol (7% and 7.5%,
respectively) (ESM Figs. 1b, 2b). Of note, the transient in-
crease in HbA1c in 2010–2012 was seen in all age groups
19 years and upwards (ESM Table 2).
HbA1c trends by sex Women consistently had slightly higher
average HbA1c than men (ESM Table 3) with differences of
1–2 mmol/mol across the years. From the regression model
the HbA1c was on average 1.7 (95% CI 1.6, 1.8) mmol/mol
higher in women than in men across the period. The increases
in HbA1c in 2010–2012 and the subsequent fall between 2012
and 2016 were of similar magnitude in both men and women,
such that the sex difference persisted over time (Fig. 1c).
Consistent with the median levels, women consistently had
slightly but significantly higher proportions of poor glycaemic
control and this sex difference persisted over time (Fig. 2c and
ESMTable 3). There was little sex difference in the proportion
of people who met targets across the time frame (ESM Figs.
1c, 2c, ESM Table 3).
HbA1c trends by area-level deprivation Large socioeconomic
differences in HbA1c levels were observed. Those living in the
most-deprived areas, indicated by the first band of SIMD
(SIMD 1), had substantially higher HbA1c levels across the
period in comparison with the band living in the least-
deprived areas (ESM Table 4). Using the regression model
the 20% of people living in the most-deprived areas had
HbA1c levels on average 8.0 (95% CI 7.4, 8.9) mmol/mol
higher than those of the 20% of people living in the least-
deprived areas. These differences were apparent in all age
groups (data not shown). The significant increases in HbA1c
in 2010–2012 and decreases in 2012–2015 were apparent
within all SIMD bands (Fig. 1d), such that the difference in
HbA1c between SIMD bands did not change over time (ESM
Table 4). Consistent with median levels of HbA1c, a much
greater proportion of people living in SIMD 1 continued to
have poor glycaemic control compared with people living in
SIMD 5 (46% vs 26%) up to the end of the evaluation period
in 2016 (Fig. 2d and ESM Table 4).
Discussion
We present trends in glycaemic trajectories in type 1 diabetes
for a national population across a 13 year period, showing a
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small overall improvement in HbA1c levels between 2004 and
2016 of about 4 mmol/mol and a corresponding decrease in
the percentage of those with poor glycaemic control.
Nonetheless, by 2016, more than one-third of all those with
type 1 diabetes still had poor glycaemic control and most did
not achieve HbA1c targets, particularly those in late
adolescence/early adulthood. That noted, the largest improve-
ment in control was seen in the two youngest age groups,
which if such improvements are sustained over time is encour-
aging, given some evidence that those who develop diabetes
younger also have the highest risks for adverse cardiovascular
outcomes [14]. However, we also found large socioeconomic
differentials in HbA1c that did not alter in this time period.
We do not know which aspects of diabetes management
may have altered HbA1c during this period. However, the
timing and larger reduction in younger people from 2012 is
consistent with an impact of age-specific policy changes. A
major policy change to quickly increase provision of insulin
pumps in Scotland was introduced in 2011, and initially was
mostly targeted towards children [6]. Although a recent study
in England and Wales did not suggest any benefit in HbA1c
reduction with insulin pumps compared with multiple daily
insulin injections in children and adolescents [15], other stud-
ies have reported improvements [16]. Apart from insulin
pump policies, the larger improvement in children may have
reflected other differences in services between paediatrics and
adult clinics (e.g. the introduction of insulin pump therapy was
accompanied by more widespread application of structured
education). However, there have also been a number of fo-
cused initiatives among the 12 paediatric clinics that care for
all of the paediatric population with type 1 diabetes in
Scotland in this time period, including ensuring comprehen-
sive education on carbohydrate counting and dynamic insulin
dosing from diagnosis, regular meetings of the 12 leads from
these centres at which key metrics on glycaemic control and
policies are reviewed. Over the time period studied, there was
no improvement in BMI or smoking, which show some rela-
tionship with HbA1c.
Although findings in older age groups were less marked,
there were reductions in the prevalence of poor glycaemic
control in all age groups. Apart from insulin pumps, the ben-
efit of other measures to improve glycaemic control remain
unclear. The Scottish Government introduced a 2 year funded
study to support Psychology in Diabetes, Psychology and
Diabetes (PiD-PaD) to improve self-management of diabetes
[17] but this psychology support is still not widely available.
Structured education, on the other hand, was recently shown
to cost-effectively improve glycaemic control with or without
Fig. 1 Estimated HbA1c
trajectories and 95% CI in all
individuals (a) and stratified by
age (b), sex (c) and SIMD band
(where 1 is the most-deprived
band) (d). Time periods in which
significant changes occurred
overall (a) and specifically for
each stratum (b, c, d) are
highlighted. Bonferroni
correction was used to maintain
an overall significance level of
0.05
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insulin pump for adults [18]. Other potential contributing fac-
tors include the increasing availability of SCI-Diabetes data in
2011, allowing health centres to compare achievement of
glycaemic control. In March 2014, the first national compar-
ison of HbA1c data for the 0–18 years age range appeared and
the data have been discussed at the National Paediatric
Diabetes Multidisciplinary Team annual meeting since then.
Starting in 2014, there was a national campaign to standardise
and tighten glycaemic targets for individuals with type 1 dia-
betes [17] and in January 2016, a national Scottish meeting set
several key core targets, which have been cascaded across
Scotland with the use of ‘Know your HbA1c charts’. At pres-
ent, we are unable to assess these specific measures across the
datasets but future studies may look into types of insulin and
change between regimens, as well as the emerging expansion
of flash glucose monitoring (FGM). These trend data from this
high-income country are encouraging, yet they also emphasise
that even in such a resource-rich setting, wherein the NHS is
free at the point of delivery and there is a concerted national
policy, there remains an enormous challenge in achieving
HbA1c targets levels in most individuals with type 1 diabetes.
It is worth noting the persistently poor glycaemic control in
those aged 19–24 years. While transition from paediatric to
adult care is rightly considered important, these data suggest a
significant problem possibly initiated in but extending beyond
the transition/transfer period. Strategies to improve control in
this vulnerable age group must address issues of healthcare
disengagement, including new models of care, greater acces-
sibility and wider availability of services such as clinical
psychology.
It would be interesting to evaluate whether other countries
have achieved greater gains over this period. The Diabetes-
Patienten-Verlaufsdokumentation (DPV) database in
Germany and Austria showed that despite substantial im-
provements in pump availability and other care aspects ex-
pected to improve HbA1c, HbA1c actually increased between
2002 and 2011 before falling thereafter [19]. Data from the
Swedish National Diabetes Registry reveal that HbA1c in-
creased by 2 mmol/mol (2.3%) between 2007 and 2012 and
decreased afterwards until 2017 [20]. Data from the USA
show that mean HbA1c levels were 66 mmol/mol (8.2%) in
individuals enrolled into the T1D Exchange Clinic Network in
2010–2012, rising to 68 mmol/mol (8.4%) in the same indi-
viduals in 2013–2014 [21]. This increase was greatest among
those aged 13–17 and 18–26 years. Also in the USA, the
National Health and Nutrition Examination Survey showed
an increasing proportion of individuals with HbA1c
≤53 mmol/mol (7%) from 1999–2002 to 2003–2006 in adults
Fig. 2 Estimated proportion and
95% CI of people with type 1
diabetes in Scotland with poor
glycaemic control (a), and
stratified by age (b), sex (c) and
SIMD band (where 1 is the most-
deprived band) (d). Poor control
was defined as HbA1c >75 mmol/
mol (9%)
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with any diabetes, followed by a plateau until 2011–2014
[22]. Although mean HbA1c values in individuals with type
1 diabetes in England seemed to be stable between 1998 and
2013 [23], the percentage of individuals achieving HbA1c
≤58 mmol/mol (7.5%) decreased from 28.7% in 2009–2010
to 27.0% in 2011–2012 before increasing to 30% in 2016–
2017 in England and Wales [24]. Increased cost sharing may
have explained the plateau in glycaemic control attainment in
the USA, whereas population changes may have contributed
towards the temporary increases in HbA1c in other countries.
Changes in care process may also play a role as HbA1c attain-
ment varies across centres in Germany, Austria, England,
Wales, USA, Sweden, Denmark and Norway [25].
We noted an increase in HbA1c between 2010 and 2012 in
most age groups, both sexes, all socioeconomic strata and all
health boards. Of note, the denominator population in Scotland
in our data was fairly stable during this time and such increase
was seen across all age groups. A potential explanation for this
increasing trend was the policy to adopt IFCC units
(mmol/mol) to replace the conventional DCCT unit (%) for
HbA1c measurements. From June 2009, a dual reporting meth-
od with both the DCCT units and IFCC units was used in
Scotland during a short adaptation period for both clinicians
and patients before fully transitioning to IFCC units from
October 2011 [26]. The impact of this change, particularly on
patient care, remains unclear. Similar increases in mean HbA1c
that coincided with the IFCC standardisation have been report-
ed in Sweden [20]. Therefore, our 2010–2012 findings may
well have resulted from biases related to the method of HbA1c
reporting rather than real increases per se.
Despite the encouraging improvement in population
HbA1c, our data showed that there are large persistent un-
changing socioeconomic inequalities in HbA1c across all age
groups. In 2016, HbA1c in the most-deprived residential cate-
gory was around 8 mmol/mol (2.9%) higher compared with
HbA1c in the least-deprived category. To put this into context,
the DCCT trial data suggest that a relative difference of 10%
in HbA1c may lead to a difference of 30–60% in microvascu-
lar complications of diabetes [27]. Although these data do not
allow us to determine the cause of the differential we ob-
served, we previously reported (in a subset of one-third of
adults with type 1 diabetes in Scotland) that those living in
more-deprived areas had a lower frequency of injections of
insulin per day, lower pump use, lower numbers of glucose
monitoring per day and were less likely to use carbohydrate
counting [28] and by inference were less likely to have re-
ceived structured education. Correspondingly, in other coun-
tries, HbA1c has been reported to be higher among people of
lower social class and lower educational attainment [29]. This
may contribute to the socioeconomic inequalities of compli-
cations in type 1 diabetes, such as diabetic retinopathy and
foot ulceration [30]. Our findings therefore prompt the need
to ensure the achievement of adequate glycaemic control
equally across the spectrum of socioeconomic status. It is
particularly important to ensure that recent innovations ex-
pected to improve glucose management in diabetes in future,
such as CGM and FGM, and widening coverage of pump
availability, reach all of those in need across socioeconomic
strata.
We also noted that sex differences in HbA1c levels persisted
over time, with better glycaemic control in men than in wom-
en. Higher HbA1c in girls, compared with boys, at time of first
diagnosis with type 1 diabetes have been reported [31]. The
higher HbA1c levels in women may underestimate the true
difference, since anaemia, more common in women is expect-
ed to lower HbA1c levels [32]. The magnitude of these sex
differences is slight in comparison with the magnitude of the
socioeconomic differences.
The strength of our study lies in the population-based data
(99.5% coverage) with repeated measures of HbA1c for over a
decade, which allowed us to estimate long-term glycaemic
trends. A limitation is our use of an area-based rather than
individual measures of socioeconomic status. In addition, we
do not yet have sufficient individual-level data on new insulin
delivery systems and other innovations, including flash mon-
itoring and structured education in diabetes management, to
enable a direct assessment of the impact within person before
and after changes in treatment. This will be the subject of
future research when the information becomes available.
Conclusion Small but meaningful improvements were seen in
glycaemic control among people with type 1 diabetes in
Scotland between 2004 and 2016 with, notably, the improve-
ments being greatest in children and adolescents, groups at
highest excess risk of premature death. Large socioeconomic
differentials in HbA1c persisted across the period. The preva-
lence of poor glycaemic control remain high and guideline
HbA1c targets are elusive for most. Clearly greater action
and use of recent innovations is needed to push further
improvements in glycaemic control in type 1 diabetes. In
particular, it will be important to monitor the impact of
specific person-level interventions including flash monitors,
widening pump use and potential use of additional oral
glucose-lowering drugs, as well as innovations in other
aspects of care, including service organisation innovations
such as digital technologies.
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